179. Williams syndrome Clinical trials / Disease details


Clinical trials : 5 Drugs : 14 - (DrugBank : 7) / Drug target genes : 8 - Drug target pathways : 32

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04095585
(ClinicalTrials.gov)
September 201416/9/2019Molecular Characterization of Patients Affected by Williams Syndrome and Autism.Molecular Investigation, Using Chromosomal Microarray and Whole Exome Sequencing, of Patients Affected by Williams Beuren Syndrome and Autism Spectrum DisorderWilliams Beuren Syndrome;Autism Spectrum DisorderGenetic: chromosomal microarray analysis (CMA) and whole exome sequencing (WES)Hospices Civils de LyonNULLCompletedN/AN/AAll6NULL
2EUCTR2007-006059-37-ES
(EUCTR)
27/05/200919/08/2008ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMSENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1.
MedDRA version: 9.1;Level: LLT;Classification code 10049644;Term: Williams syndrome
Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula
INN or Proposed INN: LOSARTAN POTASICO
Other descriptive name: LOSARTAN POTASSIUM
Programa de Medicina Molecular y Genética, Hospital Vall d´HebronNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Spain
3EUCTR2006-005745-11-FR
(EUCTR)
03/04/200806/02/2008Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomiséEfficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomisé Williams syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10049644;Term: Williams syndrome
Trade Name: LONOTEN
INN or Proposed INN: MINOXIDIL
Hospices Civils de LyonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
4NCT00768820
(ClinicalTrials.gov)
May 20017/10/2008The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeThe Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular FactorsVelocardiofacial Syndrome;Williams Syndrome;Fragile X SyndromeDrug: methylphenidate, fluoxetin, risperidoneThe Chaim Sheba Medical CenterNULLRecruitingN/AN/AAll400Phase 4Israel
5NCT00013962
(ClinicalTrials.gov)
September 19983/4/2001Vitamin D Metabolism and the Williams SyndromeVitamin D Metabolism and the Williams SyndromeWilliams SyndromeDrug: Vitamin DNational Center for Research Resources (NCRR)NULLCompleted18 Years50 YearsBothN/AUnited States